Preclinical Research

TB-500 (Thymosin Beta-4) has strong preclinical evidence for tissue repair across multiple injury models, including cardiac, skin, and corneal tissue. Human clinical data is sparse and largely confined to cardiac applications. The gap between animal and human evidence is larger than commonly represented in lay discussions.